Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Executive VP, Research & Dev | February 10, 2023 | February 13, 2023 |
| AVADEL PHARMACEUTICALS PLCAVDL · Entity 65991 | Chief Medical Officer | February 14, 2022 | February 16, 2022 |
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Director | July 29, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date February 10, 2023 · Filed February 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.97 · Expires 2033-02-09 | Direct | 237,296 |
Reported balance
After 2023-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-10 · Grant · Acquired 237,296 · Balance 237,296 F1: 25% of the shares subject to the stock option vest on the first anniversary of February 10, 2023, with the balance vesting in 36 equal monthly installments thereafter, such that the shares subject to the option will be fully vested on the fourth anniversary of such date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 50,655 |
Reported balance
After 2023-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-10 · Grant · Acquired 50,655 · Balance 50,655 F2: Each restricted stock unit is subject to the 2023 Inducement Plan and represents a contingent right to receive one share of Acadia common stock. F3: 50% of the shares subject to the restricted stock units vest on the second anniversary of February 10, 2023, with the balance vesting in two equal annual installments thereafter, such that the shares subject to the restricted stock units will be fully vested on the fourth anniversary of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option vest on the first anniversary of February 10, 2023, with the balance vesting in 36 equal monthly installments thereafter, such that the shares subject to the option will be fully vested on the fourth anniversary of such date.
F2: Each restricted stock unit is subject to the 2023 Inducement Plan and represents a contingent right to receive one share of Acadia common stock.
F3: 50% of the shares subject to the restricted stock units vest on the second anniversary of February 10, 2023, with the balance vesting in two equal annual installments thereafter, such that the shares subject to the restricted stock units will be fully vested on the fourth anniversary of such date.
AVADEL PHARMACEUTICALS PLC
Report date February 14, 2022 · Filed February 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2032-02-14 | Direct | 275,000 |
Reported balance
After 2022-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-14 · Grant · Acquired 275,000 · Balance 275,000 F1: Options become exercisable as to 68,750 ADSs on each of the first four anniversaries after the 2/14/2022 grant date. F2: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. |
Filing footnotes · ownership attribution and instrument terms
F1: Options become exercisable as to 68,750 ADSs on each of the first four anniversaries after the 2/14/2022 grant date.
F2: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
Vistagen Therapeutics, Inc.
Report date July 29, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.24 · Expires 2036-07-29 | Direct | 40,826 |
Reported balance
After 2026-07-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-29 · Grant · Acquired 40,826 · Balance 40,826 F1: Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 31, 2026 12:56 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Options (Right to Buy) · Derivative | 40,826 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001911501-26-000006 · form4-07312026_120720.xml · derivative · entry 1 Williamson Douglas J · CIK 0001911501 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,826 Underlying: Common Stock · 40,826 shares Expires 2036-07-29 F1 · derivative.exercise_date: Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant. Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 23:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 50,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008875 · doc4.xml · derivative · entry 2 Williamson Douglas J · CIK 0001911501 · Executive VP, Research & Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,655 Underlying: Common Stock · 50,655 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit is subject to the 2023 Inducement Plan and represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: 50% of the shares subject to the restricted stock units vest on the second anniversary of February 10, 2023, with the balance vesting in two equal annual installments thereafter, such that the shares subject to the restricted stock units will be fully vested on the fourth anniversary of such date. F3 · derivative.expiration_date: 50% of the shares subject to the restricted stock units vest on the second anniversary of February 10, 2023, with the balance vesting in two equal annual installments thereafter, such that the shares subject to the restricted stock units will be fully vested on the fourth anniversary of such date. Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 23:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 237,296 | $0.00 Strike: $18.97 | $0.00 |
DisclosureSEC source: 0001209191-23-008875 · doc4.xml · derivative · entry 1 Williamson Douglas J · CIK 0001911501 · Executive VP, Research & Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,296 Underlying: Common Stock · 237,296 shares Expires 2033-02-09 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest on the first anniversary of February 10, 2023, with the balance vesting in 36 equal monthly installments thereafter, such that the shares subject to the option will be fully vested on the fourth anniversary of such date. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:40 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0001179110-22-001332 · edgar.xml · derivative · entry 1 Williamson Douglas J · CIK 0001911501 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: ADSs · 275,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: Options become exercisable as to 68,750 ADSs on each of the first four anniversaries after the 2/14/2022 grant date. F2 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.